Connor, Clark & Lunn Investment Management (CC&L)
CUE icon

Connor, Clark & Lunn Investment Management (CC&L)’s Cue Biopharma CUE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-766
Closed -$65.5K – 1284
2022
Q4 		$65.5K Sell
766
-323
-30% -$29.5K ﹤0.01% 1139
2022
Q3 		$73K Buy
+1,089
New +$93.7K ﹤0.01% 1052

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CUE Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Cue Biopharma (CUE) in Q1 2023, closing a stake of 766 shares — an estimated $65.5K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CUE in Q3 2022 and held it in 2 quarters. The position peaked at $73K in Q3 2022. 63 funds tracked by Wall St. Rank hold CUE as of Q1 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Cue Biopharma position as of Q1 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 766 Cue Biopharma shares in Q1 2023, an estimated $65.5K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Cue Biopharma in Q3 2022 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Cue Biopharma position peaked at $73K in Q3 2022.
  • 63 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.